

# Faina Nakhlis

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9456278/publications.pdf>

Version: 2024-02-01

36  
papers

453  
citations

759233

12  
h-index

713466

21  
g-index

37  
all docs

37  
docs citations

37  
times ranked

497  
citing authors

#	ARTICLE	IF	CITATIONS
1	Incidence of Adjacent Synchronous Invasive Carcinoma and/or Ductal Carcinoma In-situ in Patients with Lobular Neoplasia on Core Biopsy: Results from a Prospective Multi-Institutional Registry (TBCRC) Tj ETQq1 1 0.784314 82BT /Over	1.5	46
2	Papilloma on Core Biopsy: Excision vs. Observation. <i>Annals of Surgical Oncology</i> , 2015, 22, 1479-1482.	1.5	46
3	Evaluating the Rate of Upgrade to Invasive Breast Cancer and/or Ductal Carcinoma In Situ Following a Core Biopsy Diagnosis of Non-classic Lobular Carcinoma In Situ. <i>Annals of Surgical Oncology</i> , 2019, 26, 55-61.	1.5	36
4	The Incidence of Adjacent Synchronous Invasive Carcinoma and/or Ductal Carcinoma In Situ in Patients with Intraductal Papilloma without Atypia on Core Biopsy: Results from a Prospective Multi-Institutional Registry (TBCRC 034). <i>Annals of Surgical Oncology</i> , 2021, 28, 2573-2578.	1.5	27
5	The Impact of Residual Disease After Preoperative Systemic Therapy on Clinical Outcomes in Patients with Inflammatory Breast Cancer. <i>Annals of Surgical Oncology</i> , 2017, 24, 2563-2569.	1.5	26
6	Association Between Time to Operation and Pathologic Stage in Ductal Carcinoma in Situ and Early-Stage Hormone Receptor-Positive Breast Cancer. <i>Journal of the American College of Surgeons</i> , 2020, 231, 434-447e2.	0.5	24
7	Impact of Age on Locoregional and Distant Recurrence After Mastectomy for Ductal Carcinoma In Situ With or Without Microinvasion. <i>Annals of Surgical Oncology</i> , 2019, 26, 4264-4271.	1.5	19
8	Genomic profiling of pleomorphic and florid lobular carcinoma in situ reveals highly recurrent ERBB2 and ERBB3 alterations. <i>Modern Pathology</i> , 2020, 33, 1287-1297.	5.5	19
9	Implementation of a Venous Thromboembolism Prophylaxis Protocol Using the Caprini Risk Assessment Model in Patients Undergoing Mastectomy. <i>Annals of Surgical Oncology</i> , 2018, 25, 3548-3555.	1.5	17
10	Extent of axillary surgery in inflammatory breast cancer: a survival analysis of 3500 patients. <i>Breast Cancer Research and Treatment</i> , 2020, 180, 207-217.	2.5	17
11	The Potential Impact of AMAROS on the Management of the Axilla in Patients with Clinical T1-2N0 Breast Cancer Undergoing Primary Total Mastectomy. <i>Annals of Surgical Oncology</i> , 2018, 25, 2612-2619.	1.5	14
12	Atypical Lobular Hyperplasia and Classic Lobular Carcinoma In Situ Can Be Safely Managed Without Surgical Excision. <i>Annals of Surgical Oncology</i> , 2022, 29, 1660-1667.	1.5	14
13	Metabolic characterization of inflammatory breast cancer (IBC) with baseline FDG-PET/CT: Relationship with histopathology, hormone receptor status, and pathologic response after neoadjuvant chemotherapy.. <i>Journal of Clinical Oncology</i> , 2013, 31, 1105-1105.	1.6	14
14	Evaluating the risk of underlying malignancy in patients with pathologic nipple discharge. <i>Breast Journal</i> , 2018, 24, 624-627.	1.0	11
15	Complex sclerosing lesions and radial sclerosing lesions on core needle biopsy: Low risk of carcinoma on excision in cases with clinical and imaging concordance. <i>Breast Journal</i> , 2018, 24, 133-138.	1.0	11
16	Developing a patient decision aid for women aged 70 and older with early stage, estrogen receptor positive, HER2 negative, breast cancer. <i>Journal of Geriatric Oncology</i> , 2019, 10, 980-986.	1.0	11
17	Patterns of breast reconstruction in patients diagnosed with inflammatory breast cancer: The Dana-Farber Cancer Institute's Inflammatory Breast Cancer Program experience. <i>Breast Journal</i> , 2020, 26, 384-390.	1.0	10
18	How Do We Approach Benign Proliferative Lesions?. <i>Current Oncology Reports</i> , 2018, 20, 34.	4.0	9

#	ARTICLE	IF	CITATIONS
19	Molecular determinants of post-mastectomy breast cancer recurrence. <i>Npj Breast Cancer</i> , 2018, 4, 34.	5.2	9
20	Morbidity of local therapy for locally advanced metastatic breast cancer: an analysis of the Surveillance, Epidemiology, and End Results (SEER)â€™Medicare Registry. <i>Breast Cancer Research and Treatment</i> , 2018, 169, 287-293.	2.5	8
21	Inflammatory Breast Cancer: Is There a Role for Deescalation of Surgery?. <i>Annals of Surgical Oncology</i> , 2022, 29, 6106-6113.	1.5	7
22	How Often Does Retrieval of a Clipped Lymph Node Change Adjuvant Therapy Recommendations? A Prospective, Consecutive, Patient Cohort Study. <i>Annals of Surgical Oncology</i> , 2022, 29, 3764-3771.	1.5	6
23	Metabolic Characterization of Inflammatory Breast Cancer With Baseline FDG-PET/CT: Relationship With Pathologic Response After Neoadjuvant Chemotherapy, Receptor Status, and Tumor Grade. <i>Clinical Breast Cancer</i> , 2019, 19, 146-155.	2.4	3
24	Impact of surgical complications on patient reported outcomes (PROs) following nipple sparing mastectomy. <i>American Journal of Surgery</i> , 2020, 220, 1230-1234.	1.8	3
25	Non-classic LCIS Versus Classic LCIS Versus Atypical Hyperplasia: Should Management be the Same?. <i>Current Surgery Reports</i> , 2018, 6, 1.	0.9	2
26	Presence of Non-classic LCIS Is Not a Contraindication to Breast Conservation in Patients with Concomitant Invasive Breast Cancer or DCIS. <i>Annals of Surgical Oncology</i> , 2022, 29, 7696-7702.	1.5	2
27	Premalignant Disorders of the Breast in Pregnancy and Lactation. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1252, 63-72.	1.6	1
28	Abstract PD4-06: How often does retrieval of a clipped lymph node change adjuvant therapy recommendations? A prospective consecutive patient cohort. , 2021, , .		1
29	MRI Changes in Breast Skin Following Preoperative Therapy for Patients with Inflammatory Breast Cancer. <i>Academic Radiology</i> , 2021, , .	2.5	1
30	Impact of residual nodal disease burden on sentinel node mapping and accuracy of intraoperative frozen section in node positive (cN1) breast cancer patients treated with neoadjuvant chemotherapy (NAC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 584-584.	1.6	1
31	Abstract P2-12-18: A phase 2 study of neoadjuvant systemic therapy with eribulin followed by doxorubicin and cyclophosphamide for HER2-negative inflammatory breast cancer. <i>Cancer Research</i> , 2022, 82, P2-12-18-P2-12-18.	0.9	1
32	Lobular Neoplasia. <i>Current Breast Cancer Reports</i> , 2020, 12, 36-43.	1.0	0
33	Abstract PS14-21: Refining loco-regional therapy for inflammatory breast cancer protocol in progress. , 2021, , .		0
34	Abstract PS14-09: The impact of non-classic LCIS on the natural history of DCIS. , 2021, , .		0
35	ASO Visual Abstract: Atypical Lobular Hyperplasia and Classic Lobular Carcinoma In Situ Can Be Safely Managed Without Surgical Excision. <i>Annals of Surgical Oncology</i> , 2022, 29, 1668-1669.	1.5	0
36	ASO Visual Abstract: How Often Does Retrieval of a Clipped Lymph Node Change Adjuvant Therapy Recommendations? A Prospective Consecutive Patient Cohort Study. <i>Annals of Surgical Oncology</i> , 2022, , 1.	1.5	0